Compass Therapeutics (CMPX) Expected to Announce Earnings on Monday

Compass Therapeutics (NASDAQ:CMPX) is anticipated to release its Q2 2025 earnings data before the market opens on Monday, August 11th. Analysts expect Compass Therapeutics to post earnings of ($0.13) per share for the quarter.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12). On average, analysts expect Compass Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compass Therapeutics Trading Down 2.9%

CMPX stock opened at $2.70 on Friday. The company’s 50 day moving average is $2.72 and its 200 day moving average is $2.49. The stock has a market cap of $373.36 million, a price-to-earnings ratio of -6.59 and a beta of 1.49. Compass Therapeutics has a 1-year low of $1.07 and a 1-year high of $4.08.

Analyst Ratings Changes

CMPX has been the topic of several research analyst reports. Guggenheim decreased their price objective on shares of Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. D. Boral Capital restated a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research report on Monday, April 28th. Raymond James Financial upgraded shares of Compass Therapeutics to an “outperform” rating and set a $9.00 price objective on the stock in a research report on Tuesday, July 1st. Finally, HC Wainwright restated a “buy” rating and issued a $24.00 price objective on shares of Compass Therapeutics in a research report on Monday, April 21st. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $12.67.

Institutional Trading of Compass Therapeutics

An institutional investor recently bought a new position in Compass Therapeutics stock. Creative Planning bought a new position in Compass Therapeutics, Inc. (NASDAQ:CMPX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 11,484 shares of the company’s stock, valued at approximately $30,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.